Another cocktailLilly reported positive results Tuesday from another combination with its antibody drug. A mix of bamlanivimab with the antibody etesevimab cut the chances of hospitalizations and deaths by 70% in high-risk patients.
More than 100,000 doses of the pair are currently available, and Lilly is working to produce another million doses through the middle of the year.
The US Food and Drug Administration is reviewing the cocktail, Lilly said.Antibody drugs, which mimic proteins the body naturally makes to repel viruses, are some of the few therapeutics to be successfully developed for Covid-19.
Manufactured by companies like Regeneron Pharmaceuticals Inc. and Lilly, they are being used in recently diagnosed patients who are at high.